| 1 |
34348549 | Drug treatment options for acute promyelocytic leukemia. | 2022 Jan |
2 |
| 2 |
35198449 | Clinical Response to Venetoclax and Decitabine in Acute Promyelocytic Leukemia With a Novel RARA-THRAP3 Fusion: A Case Report. | 2022 |
2 |
| 3 |
35517404 | Arsenic trioxide induces proteasome dependent TBLR1-RARα degradation to improve leukemia eradication through cell differentiation enhancement. | 2022 |
7 |
| 4 |
35622143 | PRMT5-mediated RNF4 methylation promotes therapeutic resistance of APL cells to As2O3 by stabilizing oncoprotein PML-RARα. | 2022 May 27 |
2 |
| 5 |
32854112 | A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia. | 2021 Mar 18 |
1 |
| 6 |
34310740 | RBCK1-TRIB3 decelerated the progression of acute promyelocytic leukemia. | 2021 Oct |
1 |
| 7 |
34938986 | History of Acute Promyelocytic Leukemia. | 2021 Dec |
2 |
| 8 |
32163072 | Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases. | 2020 Mar 1 |
1 |
| 9 |
32223133 | Interplay of Ubiquitin-Like Modifiers Following Arsenic Trioxide Treatment. | 2020 May 1 |
2 |
| 10 |
32455804 | PLZF-RARα, NPM1-RARα, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review. | 2020 May 21 |
2 |
| 11 |
32882258 | Arsenic induced epigenetic changes and relevance to treatment of acute promyelocytic leukemia and beyond. | 2020 Nov 1 |
2 |
| 12 |
33091440 | Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia. | 2020 Dec 15 |
1 |
| 13 |
30824184 | Identification of a point mutation PMLS214L-RARα that alters PML body organization, dynamics and SUMOylation. | 2019 Apr 9 |
3 |
| 14 |
31083206 | Characterization of atypical acute promyelocytic leukaemia: Three cases report and literature review. | 2019 May |
4 |
| 15 |
31214877 | Realgar transforming solution-induced differentiation of NB4 cell by the degradation of PML/RARα partially through the ubiquitin-proteasome pathway. | 2019 Aug |
1 |
| 16 |
31670356 | Irreversibility of arsenic trioxide induced PML/RARα fusion protein solubility changes. | 2019 Dec 11 |
2 |
| 17 |
29159499 | Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4). | 2018 Jan |
2 |
| 18 |
29387217 | Effects of lapatinib on cell proliferation and apoptosis in NB4 cells. | 2018 Jan |
2 |
| 19 |
29596829 | Influence of acute promyelocytic leukemia therapeutic drugs on nuclear pore complex density and integrity. | 2018 May 15 |
2 |
| 20 |
29973452 | [Acute promyelocytic leukemia: state-of-the-art management]. | 2018 |
2 |
| 21 |
30026570 | Molecular remission as a therapeutic objective in acute promyelocytic leukemia. | 2018 Aug |
2 |
| 22 |
28028657 | PML-RARA mutations confer varying arsenic trioxide resistance. | 2017 Apr |
1 |
| 23 |
28129653 | RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner. | 2017 Feb 14 |
1 |
| 24 |
28486108 | TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence. | 2017 May 8 |
2 |
| 25 |
28492552 | All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells. | 2017 May 11 |
4 |
| 26 |
26537301 | Varying responses of PML-RARA with different genetic mutations to arsenic trioxide. | 2016 Jan 14 |
2 |
| 27 |
26728337 | Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia. | 2016 Mar |
2 |
| 28 |
27030546 | PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells. | 2016 Jul |
7 |
| 29 |
27089249 | Molecular Characteristics and Clinical Significance of 12 Fusion Genes in Acute Promyelocytic Leukemia: A Systematic Review. | 2016 |
1 |
| 30 |
27133819 | PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. | 2016 Oct |
1 |
| 31 |
26058416 | Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer. | 2015 Dec |
2 |
| 32 |
26294332 | Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients. | 2015 Nov |
2 |
| 33 |
26414475 | Acute Promyelocytic Leukemia: A Review and Discussion of Variant Translocations. | 2015 Oct |
1 |
| 34 |
27182481 | Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia. | 2015 |
2 |
| 35 |
24720386 | RARA fusion genes in acute promyelocytic leukemia: a review. | 2014 Jun |
1 |
| 36 |
24907012 | Understanding the molecular pathogenesis of acute promyelocytic leukemia. | 2014 Mar |
2 |
| 37 |
25319615 | Molecular mechanisms of the antileukemia activities of retinoid and arsenic. | 2014 |
2 |
| 38 |
23208507 | The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability. | 2013 Oct 24 |
1 |
| 39 |
23271512 | All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene. | 2013 Jul |
1 |
| 40 |
23469683 | Combination therapy with 5-amino-4-imidazolecarboxamide riboside and arsenic trioxide in acute myeloid leukemia cells involving AMPK/TSC2/mTOR pathway. | 2013 Feb |
1 |
| 41 |
23670176 | Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. | 2013 Jun |
4 |
| 42 |
24344243 | Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. | 2013 Dec 16 |
2 |
| 43 |
22056243 | Curing APL through PML/RARA degradation by As2O3. | 2012 Jan |
2 |
| 44 |
22406621 | The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. | 2012 May 1 |
1 |
| 45 |
22692509 | The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling. | 2012 Jul 26 |
1 |
| 46 |
21613260 | Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. | 2011 Aug 11 |
1 |
| 47 |
22040992 | [PML-RARα and p21 are key factors for maintaining acute promyelocytic leukemia stem cells survival]. | 2011 Oct |
2 |
| 48 |
19468689 | MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells. | 2010 Aug |
2 |
| 49 |
19815840 | Mobilization of PML/RARalpha negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide. | 2010 Jan |
1 |
| 50 |
20378816 | Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. | 2010 Apr 9 |
3 |